Breast cancer intervention reduces depression, inflammationSeptember 01, 2009COLUMBUS, Ohio - A psychological intervention for newly diagnosed breast cancer patients with symptoms of depression not only relieves patients' depression but also lowers indicators of inflammation in the blood. Those are the findings of a new study by researchers at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC-James) and the Ohio State University Department of Psychology involving patients with stage II or III breast cancer. Patients who received a psychological therapy that reduced stress and enhanced their ability to cope experienced significant relief of depressive symptoms. Moreover, that improvement was followed by a reduction in markers of inflammation. "Previously, we knew that inflammation was associated with depression-like symptoms among cancer patients, and that both are problematic, but we did not know whether treating depression would affect inflammation," says co-author Barbara L. Andersen, professor of psychology and an OSUCCC-James researcher. "Inflammation is considered to be a cancer promoting factor, and both depression and inflammation predict increased risk of cancer death." Patients in the control group received only health and psychological assessments of their condition over the 12-month study period and showed no improvement in depression or inflammation indicators. The findings are published online in the journal Psychosomatic Medicine. "This study shows that by helping breast cancer patients with depression, they will also experience less inflammation," says study leader Dr. William E. Carson, III, professor in the division of surgical oncology and associate director for clinical research at the OSUCCC-James. First author Lisa Thornton, a post-doctoral researcher in the Department of Psychology, noted that 25 to 30 percent of cancer patients experience significant symptoms of depression. "Our findings underscore the importance of including psychological interventions in the comprehensive care of cancer patients who experience significant distress," Thornton says. The study's patients were participating in a larger clinical trial testing the effects of the same intervention on disease endpoints. Previously published findings showed that the intervention reduced the risk of breast cancer recurrence and death. This follow-up study examined records from 45 patients who entered the trial with clinically significant symptoms of depression. Twenty-three of the patients had been randomized to receive the psychological intervention plus the assessment. The remaining 22 patients received only the assessment, which consisted of a personal interview and questionnaires that evaluated mood, fatigue, health status and the influence of pain on quality of life. Blood samples were taken to assess inflammation levels, which were determined using counts of overall white blood cells and neutrophils, and the ratio of two categories of immune cells. All patients were assessed upon starting the trial, then at four, eight and 12 months. For the intervention, groups of eight to 12 patients and two psychologists met weekly for four months and monthly for eight months. By the study's end, patients receiving the intervention showed significant declines in symptoms of depression, fatigue, and pain and in the markers of inflammation. "Significant anxiety or depressive disorder symptoms are usually not recognized and might even be trivialized as a 'normal' response to cancer. However, those with clinical depression need treatment, as symptoms may not remit or even when they do, it can take months," Andersen says. Ohio State University Medical Center |
|||||||||||||||||||||
| Related Cancer Patients Current Events and Cancer Patients News Articles Common pain relief medication may encourage cancer growth Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. African-Americans with colorectal cancer have poorer outcomes, lower survival rates New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans. Researchers 'notch' a victory toward new kind of cancer drug Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Men leave: Separation and divorce far more common when the wife is the patient A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact. New mechanism explains how the body prevents formation of blood vessels Researchers at Uppsala University, in collaboration with colleagues in Sweden and abroad, have identified an entirely new mechanism by which a specific protein in the body inhibits formation of new blood vessels. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Breast density associated with increased risk of cancer recurrence A new study finds that women treated for breast cancer are at higher risk of cancer recurrence if they have dense breasts. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study's results indicate that breast cancer patients with dense breasts may benefit from additional therapies following surgery, such as radiation. Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. More Cancer Patients Current Events and Cancer Patients News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||